Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr-Jun;46(2):141-149.
doi: 10.12865/CHSJ.46.02.07. Epub 2020 Jun 30.

Single Blind, Randomised Study Regarding the Treatment of the Telangiectasia of the Lower Limbs (C1EAP) Using Polidocanol 0,5%, 1%, and Nd:YAG Laser

Nicolae Gabriel IanoȘi  1 , Carmen Daniela Neagoe  2 , Cristina Violeta Tutunaru  3 , Madalina Xenia CĂlbureanu-Popescu  4 , Liviu DrĂguȘin  1 , Gabriel GÎngeoveanu  1 , Anca Farmazon  2 , Ion PĂun  5 , Simona Laura IanoȘi  3
Affiliations

Single Blind, Randomised Study Regarding the Treatment of the Telangiectasia of the Lower Limbs (C1EAP) Using Polidocanol 0,5%, 1%, and Nd:YAG Laser

Nicolae Gabriel IanoȘi et al. Curr Health Sci J. 2020 Apr-Jun.

Abstract

The treatment of leg telangiectasias could be done with liquid sclerotherapy or Nd:YAG laser. We evaluated randomly, in a simple blind, the efficacy of the treatment with 0,5% polidocanol (POL-0,5), 1% polidocanol (POL-1) and Nd:YAG laser (LAS) on 132 patient (264 limbs) with telangiectasia of the lower limbs with less than 2mm diameter (C1EAP). The main objective was to evaluate the efficacy of the sclerotherapy (chemical compared with Nd:YAG-LAS). Secondary objectives were: possible major complications (deep thrombosis, severe burns, ischemic complications, etc.), the percentage of the local complications, the cosmetic aspect-evaluated by both the patient and the doctor and the grade of discomfort of the patient during and after the procedure. Comparing the treatment with Nd:YAG laser (LAS), polidecanol-0.5% (POL-0.5), polidecanol 1% (POL-1), it was noticed that telangiectasias smaller than 1mm led to good and very good results in all the cases treated with Nd:YAG laser and the same outcome was obtained in one third of the subjects treated with POL-0.5, vs. 47.81% of patients treated with POL-1. When telangiectasias were larger than 1mm diameter, good and very good results occurred in 86.36% of patients treated with LAS and 100% of the cases treated with POL-0.5 and POL-1. In conclusion, we consider that leg telangiectasias can be treated with good results using Nd:YAG laser or sclerotherapy with polidocanol, Nd:YAG laser being reccomended for telangiectasia under than 1 mm diameter while sclerotherapy in larger vessels.

Keywords: Nd:Yag laser; Sclerotherapy; polidocanol; telangiectasia.

PubMed Disclaimer

Figures

Table 1a
Table 1a
Statistical data for the treatment of telangiectasias-60 days
Table 1b
Table 1b
Statistical data for the treatment of telangiectasias-120 days
Figure 1
Figure 1
The diagram for the hazard function reflecting the good effect of the 3 cures in the two stages of disease, Diameter <1 (Diameter 1); Diameter >1 (Diameter 2)
Figure 2
Figure 2
Sclerotherapy with POL-1. a. Day 0, b. Day 60
Figure 3
Figure 3
Sclerotherapy with POL-0,5. a. Day 0, b. Day 60
Figure 4
Figure 4
ND:YG LASER treatment. a. Day 0, b. Day 60
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Van der Velden SK, Shadid NH, Nelemans PJ, Sommer A. How specific are venous symptoms for diagnosis of chronic venous disease. Phlebology. 2014;9(9):580–586. - PubMed
    1. Kahle B, Leng K. Efficacy of sclerotherapy in varicose veins-prospective, blinded, placebo-controlled study. Dermatol Surg. 2004;30(5):723–728. - PubMed
    1. Rabe E, Breu FX, Cavezzi A, Coleridge Smith P, Frullini A, Gillet JL, Guex JJ, Hamel-Desnos C, Kern P, Partsch B, Ramelet AA, Tessari L, Pannier F. European guidelines for sclerotherapy in chronic venous disorders. Phlebology. 2014;29(6):338–354. - PubMed
    1. Parsons ME. Sclerotherapy basics. Dermatol Clin. 2004;22(4):501–508. - PubMed
    1. Kern P, Ramelet AA, Wutschert R, Bounameaux H, Hayoz D. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg. 2004;30(3):367–372. - PubMed

LinkOut - more resources